MHRA recognises medicinal properties of cannabis

UK regulatory body the MHRA has said that products that contain cannabidiol or CBD are medicines.

CBD is a cannabis based ingredient, but there is currently only one licensed medicine, Sativex, that can be legally sold in the UK.

The drug is used to treat the symptoms of patients suffering from multiple sclerosis.

Nonetheless, cannabis itself is not recognised under UK laws as having any therapeutic value, and anyone using it, even for medical reasons, could be charged with possession.

The regulator has written to 18 companies notifying them that they have 28 days to get a licence to legally sell such products in the UK. The decision to classify products containing CBD as a medicine means manufacturers will now need to demonstrate their CBD products meet safety, quality and effectiveness standards.

Anyone selling or advertising CBD products in the UK without a licence from the MHRA could face an unlimited fine and, potentially, a two-year prison sentence

An MHRA spokeswoman commented: "If you use CBD and if you have any questions, speak to your GP or other healthcare professional.

"We have written to UK CBD stockists and manufacturers to inform them of our view.

"We can provide regulatory guidance to any company who may wish to apply for a licence."

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho